Global CAR T-Cell Therapy Market 2022-2028

Global CAR T-Cell Therapy Market 2022-2028

Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) is a type of adoptive cell transfer or immunotherapy that uses genetically modified T-cells to find and kill cancer cells. In CAR T-cell therapies, T cells are taken from the patient's blood and are changed in the lab by adding a gene for a man-made receptor (called a chimeric antigen receptor or CAR). This helps them better identify specific cancer cell antigens. The CAR T cells are then given back to the patient. According to latest analysis by Gen Consulting Company, the global CAR T-cell therapy market was USD 1,532 million in 2021 and is expected to reach USD 13,317 million in 2028 and register a CAGR of 36.2% during the forecast period, 2022-2028.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global CAR T-cell therapy market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the CAR T-cell therapy industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, target antigen, and region. The global market for CAR T-cell therapy can be segmented by product: tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), others. The Yescarta segment held the largest share of the global CAR T-cell therapy market in 2021 and is anticipated to hold its share during the forecast period. CAR T-cell therapy market is further segmented by target antigen: CD19/CD22, BCMA (B-cell maturation antigen), others. Based on region, the CAR T-cell therapy market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW). North America was the largest contributor to the global CAR T-cell therapy market in 2021.

By product:

• tisagenlecleucel (Kymriah)
• axicabtagene ciloleucel (Yescarta)
• brexucabtagene autoleucel (Tecartus)
• others

By target antigen:

• CD19/CD22
• BCMA (B-cell maturation antigen)
• others

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The global CAR T-cell therapy market report offers detailed information on several market vendors, including AbbVie Inc., Amgen Inc., AstraZeneca plc, Autolus Therapeutics plc, Bellicum Pharmaceuticals, Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics Co., Ltd., Cartesian Therapeutics, Inc., Cellectis S.A., Celyad Oncology S.A., Editas Medicine, Inc., Fortress Biotech Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Legend Biotech Corporation, Mustang Bio, Inc., Novartis International AG, Pfizer Inc., PureTech Health plc, Servier Laboratories Ltd., Takeda Pharmaceutical Company Limited, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global CAR T-cell therapy market.
• To classify and forecast the global CAR T-cell therapy market based on product, target antigen, region.
• To identify drivers and challenges for the global CAR T-cell therapy market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global CAR T-cell therapy market.
• To identify and analyze the profile of leading players operating in the global CAR T-cell therapy market.

Why Choose This Report

• Gain a reliable outlook of the global CAR T-cell therapy market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.